0001209191-21-036551.txt : 20210528 0001209191-21-036551.hdr.sgml : 20210528 20210528163551 ACCESSION NUMBER: 0001209191-21-036551 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210526 FILED AS OF DATE: 20210528 DATE AS OF CHANGE: 20210528 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Arjona Ferreira Juan Camilo CENTRAL INDEX KEY: 0001714080 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37929 FILM NUMBER: 21980897 MAIL ADDRESS: STREET 1: C/O MYOVANT SCIENCES INC. STREET 2: 2000 SIERRA POINT PARKWAY, 9TH FLOOR CITY: BRISBANE STATE: CA ZIP: 94005 FORMER NAME: FORMER CONFORMED NAME: Ferreira Juan Camilo Arjona DATE OF NAME CHANGE: 20170807 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Myovant Sciences Ltd. CENTRAL INDEX KEY: 0001679082 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: CA FISCAL YEAR END: 0331 BUSINESS ADDRESS: STREET 1: SUITE 1, 3RD FLOOR STREET 2: 11-12 ST. JAMES SQUARE CITY: LONDON STATE: X0 ZIP: SW1Y 4LB BUSINESS PHONE: 44 207-400-3351 MAIL ADDRESS: STREET 1: SUITE 1, 3RD FLOOR STREET 2: 11-12 ST. JAMES SQUARE CITY: LONDON STATE: X0 ZIP: SW1Y 4LB 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-05-26 0 0001679082 Myovant Sciences Ltd. MYOV 0001714080 Arjona Ferreira Juan Camilo C/O MYOVANT SCIENCES INC. 2000 SIERRA POINT PARKWAY, 9TH FLOOR BRISBANE CA 94005 0 1 0 0 Chief Medical Officer Common Shares 2021-05-26 4 M 0 12700 7.78 A 190567 D Common Shares 2021-05-26 4 S 0 12700 24.23 D 177867 D Stock Option (Right to Buy) 7.78 2021-05-26 4 M 0 9833 0.00 D 2028-04-15 Common Shares 9833 63717 D Stock Option (Right to Buy) 7.78 2021-05-26 4 M 0 2867 0.00 D 2027-08-14 Common Shares 2867 188400 D Shares sold pursuant to a 10b5-1 trading plan. The shares were sold at prices ranging from $24.00 to $24.87. The reporting person will provide to the SEC, the issuer or security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. 1/4 of the common shares underlying this option vested on April 16, 2019, and 1/16 of the common shares underlying this option vest each quarter thereafter, provided the Reporting Person has provided continuous service to the Issuer or its affiliates on each such date. 1/4 of the common shares underlying this option vested on August 15, 2018, and 1/16 of the common shares underlying this option vest each quarter thereafter, provided the Reporting Person has provided continuous service to the Issuer or its affiliates on each such date. /s/ Matthew Lang, Attorney-in-fact 2021-05-28